- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Del buys X-Ray Technologies
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division,
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division, Universal/X-Tek, that will sell products under the Universal and X-Tek trade names.
X-Ray Technologies was founded in 1994 and began selling systems in 1996. The company's products include lightweight full-body x-ray systems that sell in the range of $10,000 to $15,000, making them cost-effective for smaller medical facilities, according to Leonard Trugman, Del chairman, CEO, and president. X-Ray Technologies had revenues of over $1 million last year, Trugman said.
Del believes it can boost sales of the X-Ray Technologies product line by plugging the systems into the Del distribution network. Del is especially enthusiastic about the potential of the systems in international markets, such as in developing countries.
As part of the acquisition, X-Ray Technologies president and founder Randy Duffy will be general manager of the Universal/X-Tek division, reporting to John Mankowich, vice president and general manager of Del's Gendex-Del Medical Imaging subsidiary.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
